CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ): Entry into a Material Definitive Agreement
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 celz_ex41.htm FORM OF INDUCEMENT WARRANT celz_ex41.htm EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON
How this was made
The 30-second read
Why it matters
For traders, the key is that the company is issuing equity-linked warrants (and potentially related inducement/compensation), which can introduce dilution risk and affect liquidity/volatility until terms and shareholder-approval requirements are clear.
Market read
A fresh SEC filing today discloses a new warrant-based equity issuance/inducement structure, which can drive near-term trading via dilution expectations and approval/terms uncertainty.
What to watch
The excerpt omits the warrant exercise price and number of warrant shares; those two inputs largely determine dilution and valuation impact. Also, Item 5.02 suggests officer/director changes or compensatory arrangements that could shift sentiment.
Background
The document is an SEC Form 8-K describing entry into a material definitive agreement and unregistered sales of equity securities, with an exhibit providing the form of a common stock purchase (inducement) warrant dated June 30, 2026.
Ticker impact
Creative Medical Technology Holdings filed an 8-K for entry into a material definitive agreement, including an inducement warrant and unregistered equity issuance.
Likely modest negative-to-neutral bias from potential dilution/overhang, unless deal terms (exercise price/size) prove immaterial.
The excerpt confirms a material definitive agreement and a form of inducement warrant tied to unregistered sales, but key economic terms (exercise price, warrant share count) are redacted, limiting precision on magnitude.
Market effects
Microcap/small-cap biotech/medtech issuers often use warrant structures; this can reinforce sector-wide dilution-risk pricing.
No clear regional spillover indicated beyond US microcap capital markets.
Limited; the disclosure is US SEC-specific with no cross-border deal terms shown.
Counterpoint
If the warrant terms are favorable (high exercise price, small size) and shareholder approval is unlikely to be contentious, the overhang may be limited and the stock reaction could be muted.
Key entities
- issuerCreative Medical Technology Holdings, Inc.
Subject of the 8-K; entered into a material definitive agreement and disclosed an inducement warrant form tied to unregistered equity issuance.
- securityCommon Stock Purchase Warrant (Inducement Warrant)
Exhibit 4.1 form granting holders the right to purchase common stock over a multi-year term, subject to shareholder approval and exercise conditions.
- venue/regulatorNasdaq Stock Market LLC
Referenced for the requirement of shareholder approval for warrant issuance and warrant share exercise.
